Rohm Lab

Research focus

ERC Starting Grant · 2020

Targeting the crosstalk of lipid and glucose metabolism to stop cancer-associated wasting

Cachexia is the deadly outcome of many late stage cancers. It is characterized by severe wasting of adipose tissue and muscle mass, cardiac dysfunction and systemic inflammation. To date, no prognostic biomarker or efficient treatment against wasting is available, and ultimately 30% of all patients with cancer will die of cachexia. Hence, we have the critical unmet and urgent medical need of developing novel biomarkers and treatment options. Until now, research has focused on targeting either tumor-derived secreted proteins or specific aspects of organ dysfunction such as muscle atrophy. StopWaste builds on recent advances of my group in targeting adipose tissue malfunction in cachexia. My…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.